Aktuelles & Neues der YM Biosciences Inc.
YM BioSciences announces early expansion of ongoing CYT387 Phase I/II clinical study based on favorable safety and activity data
30. März 2010Press Release Source: YM BioSciences Inc. On Tuesday March 30, 2010, 7:30 am EDT
YM BioSciences Presents CYT387 Data at International Leukemia Conference
29. März 2010MISSISSAUGA, Canada – March 29, 2010 – YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), is presenting on its JAK1/2 inhibiting small molecule at the New Directions in Leukemia Research Conference in Queensland, Australia. CYT387 is...
YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
15. März 2010Press Release Source: YM BioSciences Inc. On Monday March 15, 2010, 7:30 am EDT
Media Advisory – YM BioSciences to Present at the 22nd Annual Roth Orange County Growth Stock Conference
11. März 2010MISSISSAUGA, Canada – March 11, 2010 – YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced that that Mr. David Allan, Chairman and CEO, will be presenting at the 22nd Annual ROTH Orange County Growth Stock...
YM BioSciences closes US$17.5 million financing
10. März 2010Press Release Source: YM BioSciences Inc. On Wednesday March 10, 2010, 1:00 pm EST